At a glance
- Originator Boehringer Ingelheim
- Class Antiasthmatics; Bronchodilators
- Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 17 Oct 1994 Discontinued-Preclinical for Asthma in Germany (PO)